<DOC>
	<DOCNO>NCT00517855</DOCNO>
	<brief_summary>This study second human clinical study PRTX-100 . It design assess safety single intravenous ( IV ) dose PRTX-100 , well , drug eliminate blood dosing . Additionally , study provide opportunity monitor immune system response PRTX-100 .</brief_summary>
	<brief_title>Phase 1 Study Evaluating Safety , Pharmacokinetics Pharmacodynamics PRTX-100 Healthy Adult Volunteers</brief_title>
	<detailed_description>A total 20 healthy subject enrol one two dosing cohort . Each dose cohort consist 10 subject . Within cohort , subject randomize clinical trial material ( CTM ) ( PRTX-100 placebo ) 8 subject receive PRTX-100 2 subject receive placebo . The PRTX-100 dos assess ascend fashion : 0.30 mcg/kg 0.45 mcg/kg . Dosing Cohort 2 occur Investigator review Day 0-14 safety data confers Sponsor Medical Monitor . Subjects confine clinical pharmacology research unit 5 day follow dosing . Each cohort safety , pharmacokinetic , pharmacodynamic assessment 5-day post-dose period . Subjects also follow-up assessment 6 , 7 , 10 ( ±1 ) , 14 ( ±1 ) , 30 ( ±2 ) , 60 ( ±2 ) day post-dose .</detailed_description>
	<criteria>Able provide write , informed consent Subjects good health determine medical history , physical exam , standard safety laboratory test , electrocardiogram ( ECG ) vital sign Body Mass Index ( BMI ) within range 18.532 kg/m2 Normotensive , define systolic blood pressure less equal 150 mmHg diastolic blood pressure less equal 90 mmHg Positive IgE antiSpA titer screen visit Male female subject unwilling use acceptable form birth control throughout study ( acceptable form include hormonal contraceptive use least 2 month prior screen visit , condom plus spermicide , cervical cap plus spermicide , diaphragm plus spermicide , intrauterine device plus spermicide ) Pregnant ( βhCG serum pregnancy test positive ) nursing ( lactate ) female subject Clinically significant history evidence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurological , immunological , psychiatric disorder ( ) , determine investigator designee Past medical history deep venous thrombosis thromboembolic disease , stroke , myocardial infarction , recurrent fetal loss , prior diagnosis Protein C deficiency factor V Leyden genotype Past history vasculitis autoimmune disease Clinical sign symptom acute resolve viral bacterial infection History atopic dermatitis asthma History current hepatitis carrier hepatitis B and/or hepatitis C ( Hepatitis B surface antigen [ HbsAg ] positive IgM antibody Hepatitis C [ anti Hepatitis C IgM ] ) . History AIDS determine HIV seropositive screen Any disorder would interfere absorption , distribution , metabolism , excretion drug Clinically significant abnormality screen laboratory test ( hematology , chemistry , urinalysis ) Positive urine drug test screen baseline ( e.g. , cocaine , amphetamine , barbiturate , opiate , benzodiazepine , etc . ) Positive blood test ethanol screen baseline Use dietary supplement prescription ( exception hormonal contraceptive ) , herbal , overthecounter medication ( ) ( exception acetaminophen less equal 1000 mg/day ) within 10 day prior study Day 1 Unable refrain tobacco nicotine product use period study confinement Donation blood plasma within 30 day prior dose Use ( ) investigational drug ( ) within 30 day 5 halflives ( whichever longer ) prior Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>